Evaluation of Prognostic Factors for Unresectable or Recurrent Gastric Cancer Treated with Nivolumab.

Kenji IshidoSatoshi TanabeChikatoshi KatadaYu IshibashiGen KitaharaMie OnoueYo KubotaYasuaki FurueTakuya WadaAkinori WatanabeChika Kusano

Published in: Journal of gastrointestinal cancer (2022)

Occurrence of immune-related adverse events and changes in neutrophil-to-lymphocyte ratio during nivolumab treatment may help predict the therapeutic efficacy of nivolumab monotherapy for unresectable or recurrent gastric cancer.

Keyphrases

prognostic factors
locally advanced
combination therapy
liver metastases
risk assessment
squamous cell carcinoma
open label
clinical trial
randomized controlled trial
rectal cancer
newly diagnosed